Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Sell
45
KIDS Quote, Financials, Valuation and Earnings
Last price:
$23.13
Seasonality move
:
7.7%
Day range:
$22.61 - $23.06
52-week range:
$20.25 - $35.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.50x
P/B ratio:
1.64x
Volume:
63.8K
Avg. volume:
147.1K
1-year change:
-28.33%
Market cap:
$568.4M
Revenue:
$204.7M
EPS (TTM):
-$1.75
Analysts' Opinion
-
Consensus RatingOrthoPediatrics has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $36.43, OrthoPediatrics has an estimated upside of 58.73% from its current price of $22.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $26.00 representing -13.29% downside risk from its current price of $22.95.
Fair Value
-
According to the consensus of 4 analysts, OrthoPediatrics has 58.73% upside to fair value with a price target of $36.43 per share.
KIDS vs. S&P 500
-
Over the past 5 trading days, OrthoPediatrics has underperformed the S&P 500 by -2.55% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
OrthoPediatrics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
OrthoPediatrics has grown year-over-year revenues for 17 quarters straight. In the most recent quarter OrthoPediatrics reported revenues of $52.4M.
Earnings Growth
-
OrthoPediatrics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter OrthoPediatrics reported earnings per share of -$0.46.
Enterprise value:
582.9M
EV / Invested capital:
1.39x
Price / LTM sales:
2.50x
EV / EBIT:
--
EV / Revenue:
2.74x
PEG ratio (5yr expected):
-0.16x
EV / Free cash flow:
-15.95x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$154.7M
Return On Assets:
-8.84%
Net Income Margin (TTM):
-19.15%
Return On Equity:
-11.21%
Return On Invested Capital:
-9.9%
Operating Margin:
-20.88%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $130.5M | $161.8M | $212.5M | $44.7M | $52.4M | |
| Gross Profit | $95.7M | $119.9M | $154.7M | $32.2M | $38.3M | |
| Operating Income | -$24M | -$26.9M | -$30.7M | -$9.7M | -$10.9M | |
| EBITDA | -$7.5M | -$9.3M | -$10.1M | -$4.7M | -$4.3M | |
| Diluted EPS | $0.20 | -$0.96 | -$1.75 | -$0.34 | -$0.46 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $152M | $131.4M | $225M | $203.7M | $232.1M | |
| Total Assets | $313.4M | $301M | $426.3M | $437.2M | $470.3M | |
| Current Liabilities | $36.6M | $34.3M | $35.2M | $45.8M | $37.5M | |
| Total Liabilities | $91.2M | $86M | $53.1M | $66.6M | $123.1M | |
| Total Equity | $222.1M | $215M | $373.2M | $370.6M | $347.1M | |
| Total Debt | $1.1M | $1M | $871K | $10.3M | $73.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$24M | -$27.3M | -$24.5M | -$6.7M | -$4.2M | |
| Cash From Investing | -$95.4M | $5.7M | -$15.5M | -$3.7M | -$6M | |
| Cash From Financing | $136M | $6.8M | $53.6M | -$573K | -$126K | |
| Free Cash Flow | -$34.8M | -$45.7M | -$36.5M | -$13.2M | -$8.4M | |
KIDS
Sector
Market Cap
$568.4M
$34.2M
Price % of 52-Week High
63.77%
43.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-28.33%
-41.71%
Beta (5-Year)
1.095
0.657
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$22.92
200-day SMA
Sell
Level
$25.40
Bollinger Bands (100)
Sell
Level
21.98 - 25.34
Chaikin Money Flow
Sell
Level
-506.1K
20-day SMA
Buy
Level
$21.97
Relative Strength Index (RSI14)
Buy
Level
54.65
ADX Line
Buy
Level
17.34
Williams %R
Neutral
Level
-22.4615
50-day SMA
Sell
Level
$23.02
MACD (12, 26)
Buy
Level
0.16
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Sell
Level
-25.7K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8841)
Buy
CA Score
(Annual)
Level (0.8065)
Buy
Beneish M-Score
(Annual)
Level (-2.6202)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.8217)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
Stock Forecast FAQ
In the current month, KIDS has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The KIDS average analyst price target in the past 3 months is $36.43.
-
Where Will OrthoPediatrics Stock Be In 1 Year?
According to analysts, the consensus estimate is that OrthoPediatrics share price will rise to $36.43 per share over the next 12 months.
-
What Do Analysts Say About OrthoPediatrics?
Analysts are divided on their view about OrthoPediatrics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that OrthoPediatrics is a Sell and believe this share price will drop from its current level to $26.00.
-
What Is OrthoPediatrics's Price Target?
The price target for OrthoPediatrics over the next 1-year time period is forecast to be $36.43 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is KIDS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for OrthoPediatrics is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KIDS?
You can purchase shares of OrthoPediatrics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase OrthoPediatrics shares.
-
What Is The OrthoPediatrics Share Price Today?
OrthoPediatrics was last trading at $23.13 per share. This represents the most recent stock quote for OrthoPediatrics. Yesterday, OrthoPediatrics closed at $22.95 per share.
-
How To Buy OrthoPediatrics Stock Online?
In order to purchase OrthoPediatrics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Mobileye Might Be Wall Street’s Next Big Surprise
The trend to automate vehicles started long ago when adding…
Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
99
SOC alert for May 20
Sable Offshore [SOC] is up 0.61% over the past day.
Buy
52
RGC alert for May 20
Regencell Bioscience Holdings [RGC] is up 28.63% over the past day.
Sell
40
GWLIF alert for May 20
Great-West Lifeco [GWLIF] is up 12.44% over the past day.
